Management of patients with muscle-invasive and metastatic bladder cancer

Maha Hussain*, N. Lynn Henry, Gary MacVicar

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations

Abstract

Bladder cancer is the fifth most common cancer diagnosed in the United States. Prognosis for this disease is dependent on both tumor stage and grade. Radical cystectomy has been the standard treatment for muscle-invasive local disease; however, combined-modality approaches with the use of chemotherapy are gaining momentum with data suggesting survival improvement. Patients with metastatic disease have poor long-term survival rates despite systemic multiagent chemotherapy. A variety of agents, including newer cytotoxic drugs and biologically targeted agents, are under investigation to determine the most effective regimen. The special needs of specific patient populations, such as the elderly, those with a suboptimal performance status, and patients with medical comorbidities have gained more attention. Progress in the treatment of this disease is dependent on supporting ongoing and future clinical trials.

Original languageEnglish (US)
Pages (from-to)1333-1342
Number of pages10
JournalONCOLOGY
Volume19
Issue number10
StatePublished - Sep 1 2005

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Management of patients with muscle-invasive and metastatic bladder cancer'. Together they form a unique fingerprint.

Cite this